Tango Therapeutics, Inc.
TNGX
$25.60
-$0.05-0.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -123.72M | -107.23M | -101.59M | -100.52M | -145.57M |
| Total Depreciation and Amortization | 1.92M | 2.12M | 2.28M | 2.42M | 2.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.77M | 30.72M | 27.63M | 29.03M | 28.92M |
| Change in Net Operating Assets | -62.87M | -67.16M | -67.20M | -76.75M | -34.10M |
| Cash from Operations | -143.90M | -141.55M | -138.89M | -145.82M | -148.25M |
| Capital Expenditure | -373.00K | -997.00K | -1.05M | -950.00K | -914.00K |
| Sale of Property, Plant, and Equipment | 22.00K | 2.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -524.23M | -60.83M | -39.82M | 147.86M | 132.92M |
| Cash from Investing | -524.58M | -61.83M | -40.87M | 146.91M | 132.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 975.00M | 302.92M | 222.54M | 4.09M | 3.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -668.00K | -573.00K | -36.00K | -- | -- |
| Cash from Financing | 974.33M | 302.34M | 222.50M | 4.09M | 3.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 305.86M | 98.97M | 42.75M | 5.19M | -12.29M |